Ionis Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Ionis Pharmaceuticals, Inc. (IONS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $6.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $3.50M, a 35.33% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $3.48M, a 34.71% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $3.44M, a 34.11% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.63M, a 35.35% decline year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $10.25M, a 2.06% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $10.04M, a 4.07% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $9.65M, a 79.91% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.36M, a 211.56% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $6.99M 10-Q · filed 2026-07-29 | $10.43M derived: sum of 3 quarters · filed 2026-07-29 | $12.06M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $3.48M 10-Q · filed 2026-04-29 | $6.93M derived: sum of 2 quarters · filed 2026-04-29 | $8.55M derived: sum of 3 quarters · filed 2026-04-29 | $11.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.07M derived: sum of 2 quarters · filed 2026-02-26 | $7.66M derived: sum of 3 quarters · filed 2026-07-29 | $10.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $4.22M derived: sum of 2 quarters · filed 2026-07-29 | $6.80M 10-Q · filed 2025-10-29 | $9.37M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $5.18M 10-Q · filed 2026-07-29 | $7.75M derived: sum of 3 quarters · filed 2026-07-29 | $10.26M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $2.59M 10-Q · filed 2026-04-29 | $5.16M derived: sum of 2 quarters · filed 2026-04-29 | $7.67M derived: sum of 3 quarters · filed 2026-04-29 | $10.16M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.08M derived: sum of 2 quarters · filed 2026-02-26 | $7.58M derived: sum of 3 quarters · filed 2026-02-26 | $10.04M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $5.01M derived: sum of 2 quarters · filed 2025-10-29 | $7.47M 10-Q · filed 2025-10-29 | $9.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $4.96M 10-Q · filed 2025-07-30 | $7.37M derived: sum of 3 quarters · filed 2026-02-26 | $9.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.46M 10-Q · filed 2025-04-30 | $4.88M derived: sum of 2 quarters · filed 2026-02-26 | $7.29M derived: sum of 3 quarters · filed 2026-02-26 | $9.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.82M derived: sum of 2 quarters · filed 2026-02-26 | $7.25M derived: sum of 3 quarters · filed 2026-02-26 | $9.65M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.84M derived: sum of 2 quarters · filed 2024-11-06 | $7.23M 10-Q · filed 2024-11-06 | $10.63M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.83M 10-Q · filed 2024-08-01 | $8.22M derived: sum of 3 quarters · filed 2025-02-19 | $8.89M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $2.40M 10-Q · filed 2024-05-07 | $5.79M derived: sum of 2 quarters · filed 2025-02-19 | $6.46M derived: sum of 3 quarters · filed 2025-02-19 | $7.16M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $4.06M derived: sum of 2 quarters · filed 2025-02-19 | $4.76M derived: sum of 3 quarters · filed 2025-02-19 | $5.36M 10-K · filed 2025-02-19 |
| 2022-09-30 | $670.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.37M derived: sum of 2 quarters · filed 2023-11-02 | $1.97M 10-Q · filed 2023-11-02 | $2.52M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.30M 10-Q · filed 2023-08-09 | $1.85M derived: sum of 3 quarters · filed 2024-02-21 | $2.24M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $602.00K 10-Q · filed 2023-05-03 | $1.15M derived: sum of 2 quarters · filed 2024-02-21 | $1.54M derived: sum of 3 quarters · filed 2024-02-21 | $1.93M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $940.00K derived: sum of 2 quarters · filed 2024-02-21 | $1.33M derived: sum of 3 quarters · filed 2024-02-21 | $1.72M 10-K · filed 2024-02-21 |
| 2021-09-30 | $390.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $777.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.17M 10-Q · filed 2022-11-09 | $1.55M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $781.00K 10-Q · filed 2022-08-09 | $1.16M derived: sum of 3 quarters · filed 2023-02-22 | $1.73M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $394.00K 10-Q · filed 2022-05-04 | $769.00K derived: sum of 2 quarters · filed 2023-02-22 | $1.34M derived: sum of 3 quarters · filed 2023-02-22 | $1.73M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $947.00K derived: sum of 2 quarters · filed 2023-02-22 | $1.34M derived: sum of 3 quarters · filed 2023-02-22 | $1.73M 10-K · filed 2023-02-22 |
| 2020-09-30 | $572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $963.00K derived: sum of 2 quarters · filed 2021-11-03 | $1.36M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $784.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $393.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $1.54M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |